RxDoctor Payments Data

Tabassum Yasmin, MD

Internal Medicine · East Meadow, NYNPI 1255378113

Payments from drug & device makers

$1,805in general payments, 2019–2025

Across 23 payments — averaging $78.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$1K
  • AbbVie$253
  • Viiv Healthcare Company$171
  • Merck$148
  • Sanofi Pasteur Inc.$59
  • Johnson & Johnson$28

What the payments were for

  • Consulting fees$90050%
  • Food & beverage$83046%
  • Education$282%
  • Gifts$463%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead3$1,145
AbbVie12$253
Viiv Healthcare Company3$171
Merck2$148
Sanofi Pasteur Inc.2$59
Johnson & Johnson1$28

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,805 in reported general payments places this provider in the 75th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$61,374
Medicare patients
200
Services billed
538

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala220$886,187
TivicayDolutegravir Sodium119$292,600
JulucaDolutegravir/Rilpivirine50$169,223
DescovyEmtricitabine/Tenofov Alafenam77$162,289
OdefseyEmtricitab/Rilpiviri/Tenof Ala27$113,345
CabenuvaCabotegravir/Rilpivirine15$104,795
PifeltroDoravirine49$91,075
DovatoDolutegravir Sodium/Lamivudine23$71,318
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf12$55,371
PrezcobixDarunavir/Cobicistat20$47,669
IsentressRaltegravir Potassium13$24,125
Darunavir20$18,068
Lamivudine47$7,914
Atovaquone13$7,332
Ritonavir15$2,447

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$1,145$1,048,476297 claims
Viiv Healthcare CompanyTivicay, Juluca, Cabenuva, Dovato$171$637,936207 claims
MerckPifeltro, Isentress$148$115,20062 claims
Johnson & JohnsonPrezcobix$28$47,66920 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in East Meadow

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →